This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / VistaGen Therapeutics Faces Class...
Business class action lawsuit

VistaGen Therapeutics Faces Class Action Lawsuit

Analysis based on 14 articles · First reported Mar 02, 2026 · Last updated Mar 09, 2026

Sentiment
-20
Attention
2
Articles
14
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of VistaGen Therapeutics facing a class action lawsuit, leading to investor losses. This event highlights the importance of transparent communication from publicly traded companies to maintain market confidence.

Pharmaceuticals Legal Services
Event Summary

The Schall Law Firm has initiated a class action lawsuit against VistaGen Therapeutics, alleging that the company made false and misleading statements to investors. The lawsuit claims VistaGen Therapeutics created a false impression of success for its fasedienol drug candidate's PALISADE-2 trial, downplaying the risks of clinical study failure. Investors who purchased VistaGen Therapeutics securities between April 1, 2024, and December 16, 2025, are encouraged to join the lawsuit before March 16, 2026. The firm specializes in shareholder rights litigation and represents investors globally.

Key Actions
100 Schall Law Firm filed a class action lawsuit VistaGen Therapeutics
90 VistaGen Therapeutics made false and misleading statements
Entities Involved
stock
VistaGen Therapeutics
VistaGen Therapeutics is facing a class action lawsuit for allegedly making false and misleading statements regarding the success of its fasedienol drug candidate's PALISADE-2 trial. This could lead to significant financial penalties and reputational damage for the company.
Importance 100 Sentiment -70
priv
Schall Law Firm
The Schall Law Firm is initiating and representing investors in a class action lawsuit against VistaGen Therapeutics. This event enhances the firm's visibility and business.
Importance 80 Sentiment 50
per
Brian Schall
Brian Schall is the contact person for The Schall Law Firm regarding the class action lawsuit against VistaGen Therapeutics, playing a key role in the legal proceedings.
Importance 60 Sentiment 40
govactor
United States===United States Securities and Exchange Commission
The class action lawsuit against VistaGen Therapeutics is based on alleged violations of regulations promulgated by the United States===United States Securities and Exchange Commission, highlighting its role in market oversight.
Importance 30 Sentiment 0
Relationships
Schall Law Firm related ↔ VistaGen Therapeutics
Brian Schall related ↔ Schall Law Firm
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.